Free Trial

Davis Rea LTD. Invests $3.63 Million in Xylem Inc. (NYSE:XYL)

Xylem logo with Business Services background

Davis Rea LTD. bought a new stake in Xylem Inc. (NYSE:XYL - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,419 shares of the industrial products company's stock, valued at approximately $3,634,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Xylem during the fourth quarter worth $302,734,000. Northern Trust Corp raised its holdings in shares of Xylem by 42.0% during the fourth quarter. Northern Trust Corp now owns 3,268,433 shares of the industrial products company's stock worth $379,204,000 after purchasing an additional 966,399 shares during the period. OVERSEA CHINESE BANKING Corp Ltd increased its holdings in shares of Xylem by 390.5% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,021,337 shares of the industrial products company's stock worth $122,009,000 after acquiring an additional 813,100 shares during the period. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Xylem in the 1st quarter worth about $89,828,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Xylem in the 4th quarter worth about $83,139,000. 87.96% of the stock is owned by institutional investors and hedge funds.

Xylem Stock Up 1.0%

Shares of NYSE XYL traded up $1.33 during mid-day trading on Friday, reaching $132.57. The company had a trading volume of 580,466 shares, compared to its average volume of 1,103,048. The stock has a fifty day moving average of $128.40 and a two-hundred day moving average of $123.57. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.41 and a current ratio of 1.89. The company has a market capitalization of $32.26 billion, a price-to-earnings ratio of 35.64, a PEG ratio of 2.38 and a beta of 1.12. Xylem Inc. has a 12-month low of $100.47 and a 12-month high of $143.50.

Xylem (NYSE:XYL - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The industrial products company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.04 billion. Xylem had a net margin of 10.54% and a return on equity of 10.12%. The company's revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.90 earnings per share. As a group, equities research analysts expect that Xylem Inc. will post 4.65 EPS for the current year.

Xylem Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 26th. Investors of record on Thursday, May 29th were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, May 29th. This represents a $1.60 dividend on an annualized basis and a yield of 1.21%. Xylem's payout ratio is presently 43.01%.

Wall Street Analyst Weigh In

XYL has been the topic of a number of analyst reports. Raymond James Financial raised shares of Xylem to a "hold" rating in a report on Thursday, May 15th. Royal Bank Of Canada increased their price objective on shares of Xylem from $143.00 to $147.00 and gave the stock an "outperform" rating in a report on Wednesday, April 30th. Stifel Nicolaus increased their target price on shares of Xylem from $141.00 to $162.00 and gave the company a "buy" rating in a research report on Monday. JPMorgan Chase & Co. assumed coverage on shares of Xylem in a research report on Friday, May 30th. They issued an "overweight" rating and a $148.00 target price for the company. Finally, Citigroup reiterated a "buy" rating and issued a $152.00 target price (up previously from $137.00) on shares of Xylem in a research report on Monday, July 14th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $149.29.

Read Our Latest Stock Analysis on XYL

Xylem Profile

(Free Report)

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.

Recommended Stories

Institutional Ownership by Quarter for Xylem (NYSE:XYL)

Should You Invest $1,000 in Xylem Right Now?

Before you consider Xylem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.

While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines